JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bankson, M. G.
Right arrow Articles by Cunningham, K. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bankson, M. G.
Right arrow Articles by Cunningham, K. A.

Vol. 297, Issue 3, 846-852, June 2001

3,4-Methylenedioxymethamphetamine (MDMA) as a Unique Model of Serotonin Receptor Function and Serotonin-Dopamine Interactions

Michael G. Bankson and Kathryn A. Cunningham

Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas

(+)-3,4-Methylenedioxymethamphetamine (MDMA; "ecstasy"; "X"; "E") is a popular recreational amphetamine analog that produces a unique set of effects in humans and animals. MDMA use is often associated with dance parties called "raves", but its use has increased in all segments of society and around the world. Like amphetamine, MDMA elicits hyperactivity when administered to rodents. Unlike amphetamine, which has effects mediated by the release of dopamine (DA) from nerve terminals, MDMA-induced hyperactivity is thought to be dependent upon the release of 5-hydroxtryptamine (5-HT). However, MDMA elicits large increases in synaptic concentrations of both DA and 5-HT, and the interaction between these neurotransmitters may account for the unique characteristics of the drug. Comparisons between MDMA, the selective DA releaser amphetamine, and the selective 5-HT releaser fenfluramine are used in the present discussion to highlight the ability of MDMA to model the locomotor activation induced by the interaction of DA and 5-HT. Furthermore, this review summarizes evidence to suggest that the influence of 5-HT receptors on behavioral function is dependent upon the specific neurochemical environment evoked by a given drug, specifically discussed here with regard to the interaction between 5-HT and DA systems.

0022-3565/01/2973-0846$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
M. A. Starr, M. E. Page, and B. D. Waterhouse
MDMA (3,4-Methylenedioxymethamphetamine)-Mediated Distortion of Somatosensory Signal Transmission and Neurotransmitter Efflux in the Ventral Posterior Medial Thalamus
J. Pharmacol. Exp. Ther., October 1, 2008; 327(1): 20 - 31.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
S. Doly, E. Valjent, V. Setola, J. Callebert, D. Herve, J.-M. Launay, and L. Maroteaux
Serotonin 5-HT2B Receptors Are Required for 3,4-Methylenedioxymethamphetamine-Induced Hyperlocomotion and 5-HT Release In Vivo and In Vitro
J. Neurosci., March 12, 2008; 28(11): 2933 - 2940.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
A. C. Parrott
Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy
J Psychopharmacol, January 1, 2005; 19(1): 71 - 83.
[Abstract] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. C. Jones, S. S. Lau, and T. J. Monks
Thioether Metabolites of 3,4-Methylenedioxyamphetamine and 3,4-Methylenedioxymethamphetamine Inhibit Human Serotonin Transporter (hSERT) Function and Simultaneously Stimulate Dopamine Uptake into hSERT-Expressing SK-N-MC Cells
J. Pharmacol. Exp. Ther., October 1, 2004; 311(1): 298 - 306.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
M. M. Iravani, M. J. Jackson, M. Kuoppamaki, L. A. Smith, and P. Jenner
3,4-Methylenedioxymethamphetamine (Ecstasy) Inhibits Dyskinesia Expression and Normalizes Motor Activity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Primates
J. Neurosci., October 8, 2003; 23(27): 9107 - 9115.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
N. THIRIET, B. LADENHEIM, M. T. McCOY, and J. L. CADET
Analysis of Ecstasy (MDMA)-induced transcriptional responses in the rat cortex
FASEB J, December 1, 2002; 16(14): 1887 - 1894.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.